newsfilter
← Latest News
Business Wire·

Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company's Second Therapeutic Candidate for Sensorineural Hearing Loss

Regenerative Treatment Designed to Increase Drug Exposure Through the Cochlea; Study Results Expected in H2 2023 Frequency's Lead Hearing Program, FX-322, on Track for Phase 2b Topline Results in Q1 2023 Frequency